Scarica l'app Stockscreener
0.1222
19.87%
-0.0303
Dopo l'orario di chiusura:
.12
-0.0022
-1.80%
Precedente Chiudi:
$0.1525
Aprire:
$0.1571
Volume 24 ore:
29.98M
Relative Volume:
3.60
Capitalizzazione di mercato:
$8.03M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-38.41%
1M Prestazione:
-37.08%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.1181
$0.1576
Intervallo di 1 settimana:
$0.1181
$0.2013
Portata 52W:
$0.1159
$2.22
Profusa Inc Stock (PFSA) Company Profile
Nome
Profusa Inc
Settore
Industria
Telefono
212-494-9022
Indirizzo
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Confronta PFSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.1222 | 10.02M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
128.47 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.19 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.31 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.57 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.38 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Profusa Inc Borsa (PFSA) Ultime notizie
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study By Investing.com - Investing.com Nigeria
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - The Manila Times
Profusa U.S. study met primary end points as presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - marketscreener.com
Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025 - TradingView — Track All Markets
Profusa (Nasdaq: PFSA) U.S. Lumee PAD study hits endpoints, backs potential FDA filing - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - The Manila Times
Profusa (Nasdaq: PFSA) to share US pilot PAD Lumee data at LINC 2026 in Leipzig - Stock Titan
The growth track for Profusa Inc (PFSA) has changed recently - setenews.com
Profusa, Inc. Common Stock (PFSA) -5.4% in Intraday Trading: Decline Despite Positive Clinical Update - Stocks Telegraph
Q&A: Real-time digital healthcare for 2026 - Digital Journal
Top investors say TSS Inc (TSSI) ticks everything they need - Setenews
How does Profusa Inc (PFSA) change from a tortoise to a hare? - Setenews
Profusa to Present Late Breaking U.S. Based Clinical Trial Update at Paris Vascular Insights 2025 - marketscreener.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 - The Manila Times
Profusa (PFSA) Competitors and Alternatives 2025 - MarketBeat
Profusa (PFSA) Stock Forecast and Price Target 2025 - MarketBeat
Profusa, Inc.Common Stock (NQ: PFSA - Markets Financial Content
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Profusa, Inc. (PFSA) -10.7% in Normal Trading: Decline Amid Recent Financial Update - Stocks Telegraph
Profusa raises USD 12M in gross proceeds from convertible PIPE note - Medical Buyer
Profusa Announces Q3 Highlights and Strategic Merger - TipRanks
Profusa, Inc. Announces Third Quarter 2025 Financial Results and Business Highlights - TradingView
Profusa (PFSA) 10K Form and SEC Filings 2025 - MarketBeat
Profusa Announces Third Quarter Business and Financial Highlights - The Manila Times
Profusa, Inc. SEC 10-Q Report - TradingView
[10-Q] Profusa, Inc. Quarterly Earnings Report | PFSA SEC FilingForm 10-Q - Stock Titan
Profusa, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
PFSA News Today | Why did Profusa stock go up today? - MarketBeat
Profusa (PFSA) Stock Price, News & Analysis - MarketBeat
Is Profusa Inc (PFSA) positioned for future growth? - Setenews
Profusa Delays Filing of Quarterly Report - MSN
[NT 10-Q] Profusa, Inc. SEC Filing - Stock Titan
[SCHEDULE 13G/A] Profusa, Inc. SEC Filing - Stock Titan
What is Profusa Inc (PFSA) Stock Return on Shareholders’ Capital? - Setenews
Profusa invests additional $1 million in digital treasury assets - MSN
Profusa, Inc. (PFSA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Profusa Inc (PFSA) looking to reclaim success with recent performance - setenews.com
Profusa, Inc. (PFSA) stock price, news, quote and history - Yahoo! Finance UK
[8-K] Profusa, Inc. Reports Material Event | PFSA SEC FilingForm 8-K - Stock Titan
Profusa outlines EU launch of tissue oxygen monitoring in 2026 - Investing.com India
Profusa outlines revenue plan, targets EU commercial launch of Lumee in early Q2 2026 - MSN
Profusa outlines EU launch of tissue oxygen monitoring in 2026 By Investing.com - Investing.com South Africa
Profusa Unveils Strategic Plan for Revenue Growth - TipRanks
Profusa, Inc. Outlines Path to $250 Million Revenue by 2030 - TradingView
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches - The Manila Times
Profusa Outlines Potential Path to $250 Million Revenue by - GlobeNewswire
Profusa (PFSA) Stock Skyrockets 36% on Milestone News – Can This Biotech Sensor Play Rebound? - ts2.tech
Why Profusa (PFSA) Stock Soared 36% After Hours? - Benzinga
[424B3] Profusa, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Profusa Inc Azioni (PFSA) Dati Finanziari
Non sono disponibili dati finanziari per Profusa Inc (PFSA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.42%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):